ClinicalTrials.Veeva
Menu

Find clinical trials for Pancreatic Cancer in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Adenocarcinoma
Cancer
Carcinoma
Colorectal Cancer
Lung Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck

Pancreatic Cancer trials near Valencia, VC, ESP:

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer (LAPIS)

with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic...

Active, not recruiting
Pancreatic Cancer Non-resectable
Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

Phase 3

FibroGen
FibroGen

Valencia, Spain and 89 other locations

A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer...

Enrolling
Pancreatic Adenocarcinoma
Metastatic
Genetic: VCN-01
Drug: Gemcitabine

Phase 2

Theriva Biologics

Valencia, Spain and 16 other locations

and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...

Active, not recruiting
Neoplasms Pancreatic
Pancreatic Adenocarcinoma
Drug: Gemcitabine - 21 day cycle
Drug: Lomustine

Phase 2

Actuate Therapeutics

Valencia, Spain and 65 other locations

with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C \& D) to evaluate the safety and to...

Active, not recruiting
Papillary Thyroid Cancer
Non Small Cell Lung Cancer
Drug: Nivolumab and Nal-IRI/5-FU/LV - Expansion
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion

Phase 1, Phase 2

Famewave

Valencia, Spain and 17 other locations

This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immun...

Enrolling
Pancreatic Cancer Harboring NRG1 Fusion
NSCLC Harboring NRG1 Fusion
Drug: zenocutuzumab (MCLA-128)

Phase 2

Merus

Valencia, Spain and 64 other locations

The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given...

Active, not recruiting
BRAF Mutant Colorectal Cancer
Lung Squamous Cell Cancer
Biological: PDR001
Drug: LGK974

Phase 1

Novartis
Novartis

Valencia, Comunidad Valenciana, Spain and 19 other locations

consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometri ...

Enrolling
Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
Drug: Trastuzumab deruxtecan

Phase 2

AstraZeneca
AstraZeneca

Valencia, Spain and 113 other locations

This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinic...

Enrolling
Endometrial Cancer
Epithelial Ovarian Cancer
Drug: Nivolumab
Drug: XB002

Phase 1

Exelixis
Exelixis

Valencia, Spain and 91 other locations

Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated G...

Active, not recruiting
Non-small Cell Lung Cancer
Colorectal Cancer
Drug: Placebo for ponsegromab
Drug: ponsegromab

Phase 2

Pfizer
Pfizer

Valencia, Valenciana, Comunitat, Spain and 123 other locations

To assess:* efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification...

Enrolling
Colon Cancer
Lung Cancer
Drug: APL-101 Oral Capsules

Phase 2

Apollomics

Valencia, Spain and 90 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems